Nuclea Biotechnologies Receives $5,000,000 Series C Funding
-
Feed Type
-
Link
http://www.venturedeal.com/Search/SearchResultTransactionDetail.aspx?TransactionId=be44b491-82b9-432f-bd94-e00dd742caa4&Preview=1 -
Date
8/2/2012 -
Company Name
Nuclea Biotechnologies -
Mailing Address
105 South Street Pittsfield, MA 01201 -
Company Description
Nuclea Biotechnologies’ primary mission is to conduct genomic research in the oncology field so as to discover biomarkers and gene or protein expression profiles that are unique to oncologic diseases. -
Website
http://www.nucleabiomarkers.com -
Transaction Type
Venture Equity -
Transaction Amount
$5,000,000 -
Transaction Round
Series C -
Proceeds Purposes
The company will use the proceeds to support clinical trials and new hires related to the development of its fatty acid synthase tests for prostate and breast cancers. -
M&A Terms
-
Venture Investor
Undisclosed
